Smoking load reduction is insufficient to downregulate miR-301b, a lung cancer promoter

Imagem de Miniatura
Arquivos
art_ARCAS_Smoking_load_reduction_is_insufficient_to_downregulate_miR301b_2020.PDF (1.18 MB)
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2020
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
NATURE RESEARCH
Autores
LIN-WANG, Hui Tzu
SOUSA, Marcio Goncalves de
HIRATA, Mario Hiroyuki
Citação
SCIENTIFIC REPORTS, v.10, n.1, article ID 21112, 9p, 2020
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Several circulating miRNAs identified in the plasma of smokers have been implicated as promoters of nasopharyngeal and lung carcinoma. To investigate the plasma profile of miRNAs in subjects who reduces the number of smoked cigarettes and who quit after six months. We accompanied 28 individuals enrolled in a Smoking Cessation Program over 6 months. At Baseline, clinical characteristics, co-morbidities, and smoking history were similar among subjects. After 6 months, two groups were defined: who successfully quitted smoking (named ""quitters"", n=18, mean age 57 years, 11 male) and who reduced the number of cigarettes smoked (20-90%) but failed to quit smoking (named ""smokers"", n=10, mean age 52 years, 3 male). No significant clinical changes were observed between groups at baseline and after a 6-month period, however, quitters showed significant downregulations in seven miRNAs at baseline: miR-17 (-2.90 -fold, p=0.029), miR-20a (-3.80-fold, p=0.021); miR-20b (-4.71-fold, p=0.027); miR-30a (-3.95-fold, p=0.024); miR-93 (-3.63-fold, p=0.022); miR-125a(-1.70 -fold, p= 0.038); and miR-195 (-5.37-fold, p=0.002), and after a 6-month period in 6 miRNAs: miR-17 (-5.30-fold, p=0.012), miR-20a (-2.04-fold, p=0.017), miR-20b (-5.44-fold, p=0.017), miR-93 (-4.00-fold, p=0.041), miR-101 (-4.82-fold, p=0.047) and miR-125b (-3.65-fold, p=0.025). Using time comparisons, only quitters had significant downregulation in miR-301b (-2.29-fold, p=0.038) after 6-month. Reductions in the number of smoked cigarettes was insufficient to change the plasma profile of miRNA after 6 months. Only quitting smoking (100% reduction) significantly downregulated miR-301b related to hypoxic conditions, promotion of cell proliferation, decreases in apoptosis, cancer development, and progression as increases in radiotherapy and chemotherapy resistance.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/39805
Referências
  1. Aldi GA, 2018, SUBST ABUS, V39, P289, DOI 10.1080/08897077.2018.1439802
  2. ANDERSEN I, 1983, EUR J RESPIR DIS, V64, P37
  3. Andersson BA, 2019, BIOMARKERS, V24, P180, DOI 10.1080/1354750X.2018.1539764
  4. Bauld L, 2010, J PUBLIC HEALTH-UK, V32, P71, DOI 10.1093/pubmed/fdp074
  5. Bough KJ, 2013, CLIN PHARMACOL THER, V93, P526, DOI 10.1038/clpt.2013.57
  6. Brasil. Ministerio da Saude (MS), REL REC CON NO 468 V
  7. Brose LS, 2013, ADDICT BEHAV, V38, P2529, DOI 10.1016/j.addbeh.2013.04.006
  8. Chen B, 2019, J CANCER, V10, P5793, DOI 10.7150/jca.30336
  9. Cho Y. J, HLTH ED BEHAV, V45, P32
  10. de Oliveira-Maul JP, 2013, CHEST, V143, P1091, DOI 10.1378/chest.12-1183
  11. Decrarner M, 2008, RESP MED, V102, pS3, DOI 10.1016/S0954-6111(08)70003-9
  12. Deveci SE, 2004, RESP MED, V98, P551, DOI 10.1016/j.rmed.2003.11.018
  13. Duan BY, 2019, J CANCER, V10, P6681, DOI 10.7150/jca.30757
  14. Feldman A, 2017, ANN HUM GENET, V81, P99, DOI 10.1111/ahg.12188
  15. Fiore MC, 2008, RESP CARE, V53, P1217
  16. Fu X, 2018, EXP THER MED, V16, P4553, DOI 10.3892/etm.2018.6785
  17. Hecht SS, 2004, JNCI-J NATL CANCER I, V96, P107, DOI 10.1093/jnci/djh016
  18. Huang WM, 2020, CELL DEATH DIFFER, V27, P1709, DOI 10.1038/s41418-019-0455-x
  19. Izzotti A, 2016, AM J CANCER RES, V6, P1461
  20. Jiang ZY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094639
  21. Jimenez FR, 2016, EXP LUNG RES, V42, P440, DOI 10.1080/01902148.2016.1261309
  22. Josephs L, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.02114-2016
  23. Judge K, 2005, ADDICTION, V100, P46, DOI 10.1111/j.1360-0443.2005.01027.x
  24. Kotz D, 2012, NICOTINE TOB RES, V14, P900, DOI 10.1093/ntr/ntr305
  25. Lee HY, 2015, MOL MED REP, V11, P2034, DOI 10.3892/mmr.2014.2890
  26. Li P, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1235-8
  27. Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
  28. Mestdagh P, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-6-r64
  29. Miller MR, 2005, EUR RESPIR J, V26, P153, DOI 10.1183/09031936.05.00034505
  30. Momi N, 2014, TRENDS MOL MED, V20, P36, DOI 10.1016/j.molmed.2013.10.005
  31. Nakagawa NK, 2005, CHEST, V128, P2772, DOI 10.1378/chest.128.4.2772
  32. Nicola ML, 2014, CHEST, V145, P998, DOI 10.1378/chest.13-1355
  33. Utiyama DMO, 2016, CLINICS, V71, P344, DOI 10.6061/clinics/2016(06)10
  34. Parris BA, 2019, J THORAC DIS, V11, pS2155, DOI 10.21037/jtd.2019.10.54
  35. Pereira Carlos Alberto de Castro, 2007, J. bras. pneumol., V33, P397, DOI 10.1590/S1806-37132007000400008
  36. Perkins KA, 2013, NICOTINE TOB RES, V15, P978, DOI 10.1093/ntr/nts205
  37. Pezzuto A, 2018, J BREATH RES, V12, DOI 10.1088/1752-7163/aad0a8
  38. Reichert Jonatas, 2008, J. bras. pneumol., V34, P845, DOI 10.1590/S1806-37132008001000014
  39. Ricarte Filho Júlio C.M., 2006, Arq Bras Endocrinol Metab, V50, P1102, DOI 10.1590/S0004-27302006000600018
  40. Rizk Sanaa A., 2018, Journal of Genetic Engineering and Biotechnology, V16, P53, DOI 10.1016/j.jgeb.2018.02.003
  41. Rodu Brad, 2006, Harm Reduct J, V3, P37, DOI 10.1186/1477-7517-3-37
  42. Schafnitzel A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54956-8
  43. Schembri F, 2009, P NATL ACAD SCI USA, V106, P2319, DOI 10.1073/pnas.0806383106
  44. Shen GM, 2013, ACTA PHARMACOL SIN, V34, P336, DOI 10.1038/aps.2012.195
  45. Shi YK, 2016, J CANCER RES THER, V12, P693, DOI 10.4103/0973-1482.146130
  46. Smith PH, 2016, PREV MED, V92, P135, DOI 10.1016/j.ypmed.2016.07.013
  47. Sun YM, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-6
  48. Takahashi K, 2013, TOXICOL APPL PHARM, V272, P154, DOI 10.1016/j.taap.2013.05.018
  49. Tashkin DP, 2015, SEMIN RESP CRIT CARE, V36, P491, DOI 10.1055/s-0035-1555610
  50. Underner M, 2010, REV MAL RESPIR, V27, P293, DOI 10.1016/j.rmr.2009.09.004
  51. Van Pottelberge GR, 2011, AM J RESP CRIT CARE, V183, P898, DOI 10.1164/rccm.201002-0304OC
  52. Wang G, 2005, PLOS ONE, V24, DOI [10.1371/journal. pone.01208, DOI 10.1371/JOURNAL.PONE.01208]
  53. Wang W, 2016, MED SCI MONITOR, V22, P2126, DOI 10.12659/MSM.896832
  54. Willemse BWM, 2004, EUR RESPIR J, V23, P464, DOI 10.1183/09031936.04.00012704
  55. World Health Organization, 2019, WHO REPORT GLOBAL TO
  56. Wu DG, 2016, CELL PROLIFERAT, V49, P476, DOI 10.1111/cpr.12264
  57. Wu KL, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071611
  58. Yang IA, 2011, EXPERT OPIN THER TAR, V15, P439, DOI 10.1517/14728222.2011.555400

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - FM/MFT
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - HC/IMREA
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/05
Carregar mais